Application No. 10/560,103

Submission of an Information Disclosure Statement Dated March 10, 2006



MAR 1 8 2006

ppl. No

10/560,103

Confirmation No.: Unknown

Applicant

Kelly M. McNagny et al.

Filed

June 9, 2004

Title

Methods for Detecting and Treating Cancer Using

Podocalyxin and/or Endoglycan

TC./A.U.

: Unknown

Examiner

Unknown

Docket No.

7685-102

Customer No.

001059

Honorable Commissioner for Patents P. O. Box 1450 Alexandria, Virginia 22313–1450

FILING OF AN INFORMATION DISCLOSURE STATEMENT

In accordance with 37 CFR 1.97 and 1.98, and in recognition of the duty of disclosure set forth in 37 CFR 1.56, Applicant hereby submits an Information Disclosure Statement on Form PTO-1449 containing a listing of publications of which Applicant is aware. Applicant is also submitting the references listed on the Information Disclosure Statement.

All of the patents and publications submitted herewith are in the English language. Accordingly a concise explanation of the relevance of the documents is not required.

The Examiner is requested to indicate consideration of these documents by initialing the appropriate column.

Applicants reserve the right to contest the applicability of any of these documents as prior art against the subject application. If the Examiner has any questions concerning this Information Disclosure Statement, he/she is requested to contact the undersigned. Entry of the enclosed Information Disclosure Statement is believed to be in order and is respectfully requested.

Application No. 10/560,103 Submission of an Information Disclosure Statement Dated March 10, 2006

This Information Disclosure Statement is being filed before the issuance of a first official action, and therefore no fees are required. However, please charge our deposit account No. 02-2095 if such a fee is required.

Respectfully submitted,

Kelly M. McNagny et al.

Micheline Gravelle Registration No. 40,261

Dated: March 10, 2006

Bereskin & Parr Box 401, 40 King Street West Toronto, Ontario, Canada M5H 3Y2

(416) 364-7311

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitution form 1449A/PTO

INFORMATION DISCLOSURE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

MAR 1 3 2006

Complete if Known			
Application Number	10/560,103		
Filing Date	Unknown		
First Named Inventor	Kelly M. McNagny		
Art Unit	Unknown		
Examiner Name	Unknown		
Attorney Docket Number	7685-102		

U.S. PATENT DOCUMENTS					
Examiner Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant	
	Number - Kind Code ² (if known)			Passages or Relevant Figures Appear	
	1	US-6,395,882 B1	05-28-2002	The Regents of the University of California	
	2	US-			
	3	US-			
	4	US-			
		US-			
		US-			
		US-			
	I	US-		· · · · · ·	
		US-			
	1	US-			
		US-	-		

	FOREIGN PATENT DOCUMENTS					
Examiner Cite	Cite	Foreign Patent Document	Publication Date MM-DD-YYYY Name of Patentee or Applicant of Cited Document	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
Initials*	No.1	Country Code ³ - Number ⁴ - Kind Code ⁵ (<i>if known</i>)				T⁵
	1	WO 02/079492	10-10-2002	EOS Biotechnology		
	2					
	3					
	4					

Examiner	 Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patient Documents at www.uspto.gov or MPEP 901.04. There Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patient documents, the indication of the year of the reign of the Emperor must precede the serial number of the patient document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of

Complete if Known			
Application Number	Unknown		
Filing Date	Unknown		
First Named Inventor	Kelly M. McNagny		
Art Unit	Unknown		
Examiner Name	Unknown		
Attorney Docket Number	7685-102		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²	
	1	SCHOPPERLE, W.M. et al., Human Embryonal Carcinoma Tumor Antigen, Gp200/GCTM-2, is podocalyxin, Biochem. Biophys. Res. Comm., vol. 300, no. 2, January 10, 2003, pages 285-290.		
	2	FIEGER, C.B. et al., Endoglycan, A member of the CD34 family, functions as an L-selectin ligand through modification with tyrosine sulfation and sialyl Lewis x., J. Biol. Chem., vol. 278, no. 30, May 16, 2003.		
	3	SOMASIRI, A. et al., Overexpression of the anti-adhesin podocalyxin is an independent predictor of breast cancer progression, Cancer Res., vol. 64, August 1, 2004, pages 5068-5073.		
	4			
	5			
	6			
	7			
	8			
	9			
	10			
	11			

Examiner	 Date	
Signature	Considered	
0.9	00110100100	

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance